University Hospitals Cleveland Medical Center,
Foley Medical Building, 2061 Cornell Road, Room 207, Cleveland, OH 44106-5076
Tanzania
Short Communication
Treatment of SLE and Secondary Sjogren’s Syndrome with Belimumab
Author(s): Riaz Ahmad, Charles J Malemud and Ali D AskariRiaz Ahmad, Charles J Malemud and Ali D Askari
Belimumab neutralizes the soluble form of B-cell activating factor and is FDA-approved for treating Systemic Lupus Erythematosus (SLE). In this retrospective analysis 16 female SLE patients had been treated with belimumab according to FDA guidelines along with any immunosuppressive drugs or antimalarial drugs they had previously been prescribed, in addition to prednisone. Thirteen of 16 patients presented with serologic evidence of positive anti-nuclear antibody titer while several other SLE patients also had clinical evidence of secondary Sjogren’s Syndrome (2°SS), the latter supported by sicca symptoms and positive anti-Sjogren’s-syndrome-related antigen A antibody titer. Changes in the SLE symptoms after belimumab therapy was assessed by the recipient’s responses on the Short Form-36 questionnaire. Ten of the 16 SLE patients reported a decrease in arthralgias .. Read More»
DOI:
10.4172/2476-1966.1000112
